Dr. Reddy's launches Loqtorzi biosimilar in India under the brand name Zytorvi for treating adults with recurrent or ...

In 2023, Dr Reddy's signed a licensing and commercialisation agreement with Shanghai Junshi Biosciences for Toripalimab ...

In 2023, Dr. Reddy's entered into a license and commercialisation agreement with Shanghai Junshi Biosciences Co. Ltd for ...

Dr Reddy’s Laboratories launches Toripalimab, the first immuno-oncology drug for nasopharyngeal carcinoma, in India.

Dr. Reddy's Laboratories launched Zytorvi (Toripalimab), a novel immunotherapy drug for recurrent or metastatic ...

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together ...

Dr. Reddy’s Laboratories has launched Toripalimab, a New Biological Entity (NBE) in the domestic market. “The launch of ...

Dr Reddy's Laboratories has launched toripalimab, an immune oncology drug for adults with recurrent or metastatic ...

News on Telangana Today, Metastatic nasopharyngeal carcinoma (RM-NPC) latest news, Metastatic nasopharyngeal carcinoma (RM-NPC) news, | Telangana Today ...

Dr. Reddy's Laboratories Ltd. (RDY) said that it has launched Toripalimab in India, the first and only immuno-oncology drug approved ...

Dr. Reddy’s Laboratories on Thursday announced the launch of Toripalimab in India to treat adults with Nasopharyngeal ...